JPMorgan has commenced coverage of CG Oncology, assigning the company an Overweight rating with a target price of $41. This signals optimism about CGON's future prospects. The firm highlights CG Oncology's pioneering efforts in developing an oncolytic viral therapy aimed at treating non-muscle invasive bladder cancer. Key to their strategy is their lead product, Cretostimogene, which is poised to become a significant contender in the bladder-sparing treatment market. This comes at a time when there is a notable shortage of the traditional treatment, Bacillus Calmette-Guerin, showcasing Cretostimogene's potential importance in this space.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for CG Oncology Inc (CGON, Financial) is $62.63 with a high estimate of $82.00 and a low estimate of $23.00. The average target implies an upside of 125.76% from the current price of $27.74. More detailed estimate data can be found on the CG Oncology Inc (CGON) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, CG Oncology Inc's (CGON, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
